Clinical Trials Logo
  1. Home
  2. Carcinoma Breast Stage IV
  3. NCT00433095

Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer

Carcinoma Breast Stage IV Clinical Trial

Clinical Trial Summary

1st-line treatment of HER2/neu overexpressing breast cancer

Clinical Trial Description

The combination of vinorelbine and trastuzumab was demonstrated to be highly effective in several trials showing response rates in the range of 59-78%. This combination is characterized by good tolerability and can be applied for a prolonged period without the risk of major cumulative toxicity The availability of oral vinorelbine promises a further simplification of therapy. The present trial therefore investigates the safety and efficacy of a combined treatment with trastuzumab and oral vinorelbine. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00433095
Study type Interventional
Source Ludwig-Maximilians - University of Munich
Contact
Status Completed
Phase Phase 2
View Details
See also
  Status Clinical Trial Phase
Completed NCT03511781 - Palliative Hypofractionated Radiotherapy in Advanced Incurable Breast Cancer N/A
Completed NCT00199212 - PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2 Phase 1
Recruiting NCT06281860 - Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration Phase 1
Active, not recruiting NCT02755272 - A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer Phase 2
Withdrawn NCT02140437 - Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC Phase 2
Terminated NCT02183805 - Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer Phase 2
Terminated NCT01531764 - BIBW 2992 (Afatinib) and Vinorelbine Phase 2
Completed NCT00669565 - Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer Phase 2
Completed NCT01631552 - Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Phase 1/Phase 2
Withdrawn NCT01906112 - Role of Surgery for the Primary in Patients With Breast Cancer Stage IV. Phase 3
Recruiting NCT02161315 - Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer N/A